| ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More | Ben Fidler | 10/01/19 | National |
| Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck | Ben Fidler | 07/24/19 | New York |
| Neon’s Early Vaccine Study Is a Peek at Immunotherapy’s Third Wave | Ben Fidler | 07/15/19 | Boston |
| Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More | Alex Lash | 06/28/19 | National |
| ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More | Alex Lash | 06/05/19 | National |
| Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer? | Alex Lash | 05/30/19 | National |
| Immunotherapy Is Now Here For Breast Cancer. What Are Its Prospects? | Ben Fidler | 05/29/19 | National |
| Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More | Ben Fidler | 05/10/19 | National |
| AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results | Ben Fidler | 04/03/19 | National |
| In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo | Ben Fidler | 01/24/19 | New York |
| Bio Roundup: Aimmune Drama, Shutdown Blues, Perlmutter Talks Cancer | Ben Fidler | 01/18/19 | National |
| In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B | Ben Fidler | 01/03/19 | National |
| Bio Roundup: CRISPR Babies, Blood Diseases, Big Cancer Nod & More | Alex Lash | 11/30/18 | National |
| ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front | Alex Lash | 10/23/18 | National |
| Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End | Ben Fidler | 10/19/18 | National |
| A Year Early, Merck Touts Good Kidney Cancer News to Push Rival BMS | Alex Lash | 10/18/18 | New York |
| Bristol Stumbles in Lung Cancer Again as Rivals Play Catch-Up | Ben Fidler | 10/12/18 | New York |
| FDA’s Latest Cancer Approval Underscores Immunotherapy Nobel Prize | Alex Lash | 10/01/18 | National |
| Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison, Honjo | Corie Lok | 10/01/18 | National |
| Bristol Nabs Immunotherapy’s First FDA Nod for Small Cell Lung Cancer | Ben Fidler | 08/17/18 | New York |
| Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More | Alex Lash | 08/03/18 | National |
| With Roche Data, Cancer Combos Post First Win Vs. Small Cell Lung Cancer | Ben Fidler | 06/25/18 | San Francisco |
| ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More | Ben Fidler | 06/05/18 | National |
| IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down | Ben Fidler | 05/31/18 | National |
| Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More | Alex Lash | 04/20/18 | National |
| For More Lung Cancer Patients, the Promise of No Chemo Looms Larger | Alex Lash | 04/16/18 | National |
| With New Data, Drug Combos, Lung Cancer Experts Scramble to Keep Pace | Ben Fidler | 04/11/18 | National |
| Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks | Ben Fidler | 03/23/18 | National |
| For Latest Combo, Merck Bets $394M on Viralytics, Cancer-Fighting Viruses | Ben Fidler | 02/21/18 | New York |
| Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost | Alex Lash | 02/14/18 | New York |
